Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling
Giorgia Zanetti, Sameena Nikhat, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Andrew K. Sewell, Audrey V. Parent, Remi J. Creusot, Megan Sykes, Mohsen Khosravi-Maharlooei
Giorgia Zanetti, Sameena Nikhat, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Andrew K. Sewell, Audrey V. Parent, Remi J. Creusot, Megan Sykes, Mohsen Khosravi-Maharlooei
View: Text | PDF
Research In-Press Preview Immunology

A universal platform for TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

  • Text
  • PDF
Abstract

Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.

Authors

Giorgia Zanetti, Sameena Nikhat, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Andrew K. Sewell, Audrey V. Parent, Remi J. Creusot, Megan Sykes, Mohsen Khosravi-Maharlooei

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts